key: cord-0300801-5n849h51
authors: Slimings, C.; Riley, T. V.
title: Antibiotics and hospital-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.
date: 2021-02-23
journal: nan
DOI: 10.1101/2021.02.21.21252172
sha: 35de8185fe9a6bed4af91ceab0af7d4f9e357f50
doc_id: 300801
cord_uid: 5n849h51

Background: Clostridioides difficile infection (CDI) is the most common cause of healthcare facility associated (HCFA) infectious diarrhoea in high income countries. Antibiotic use is the most important modifiable risk factor for CDI. The most recent systematic review covered studies published until 31st December 2012. Objectives: To update the evidence for epidemiological associations between specific antibiotic classes and HCFA CDI for the period 1st January 2013 to 31st December 2020. Data sources: PubMed, Scopus, Web of Science Core Collection, WorldCat, and Proquest Dissertations and Theses. Study eligibility criteria, participants and exposures: Eligible studies were those conducted among adult hospital inpatients, measured exposure to individual antibiotics or antibiotic classes, included a comparison group, and measured the occurrence of HCFA CDI as an outcome. Study appraisal and synthesis methods: The Newcastle Ottawa Scale for the Assessment of Quality was used to appraise study quality. To assess the association between each antibiotic class and HACDI, a pooled random effects meta-analysis was undertaken. Metaregression and sub-group analysis was used to investigate study characteristics identified a priori as potential sources of heterogeneity. Results: Carbapenems, and 3rd and 4th generation cephalosporin antibiotics remain most strongly associated with HCFA CDI, with cases more than twice as likely to have recent exposure to these antibiotics prior to developing CDI. Modest associations were observed for fluoroquinolones clindamycin, and betalactamase inhibitor combination penicillin antibiotics. Limitations: Individual study effect sizes were variable and heterogeneity was observed for most antibiotic classes. Availability of a single reviewer to select, extract and critically appraise the studies. Conclusions: This review provides the most up to date synthesis of evidence in relation to the risk of HCFA CDI associated with exposure to specific antibiotic classes. Studies were predominantly conducted in North America or Europe and more studies outside of these settings are needed.

Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated infections and the most common cause of health care facility-associated (HCF) infectious diarrhoea in high-income countries. 1 C. difficile is a toxin-producing, anaerobic spore forming bacterium that is transmitted via the faecal-oral route. 2 Symptoms range from mild diarrhoea to life-threatening conditions such as pseudomembranous colitis and toxic megacolon, and recurrence occurs among approximately 20% of cases following an initial episode. 2 CDI is associated with a protracted length of stay incurring substantial direct and indirect healthcare utilisation costs. [3] [4] [5] Incidence rates of healthcare facilityassociated (HCFA) CDI are geographically and temporally variable but have generally increased in the past 20 years. 1, 6, 7 Explanations for the increasing occurrence include increased testing and more sensitive diagnostic tests, increased use of broad-spectrum antibiotics, inadequate prevention measures, ageing population and emergence of community strains. 7 Antibiotic use is the most important modifiable risk factor for CDI. Antibiotic exposure alters the natural flora of the intestines allowing C. difficile to proliferate. Other important risk factors include advanced age, increased number of comorbidities or severe underlying disease, and duration of healthcare exposure. 8, 9 A longer duration of hospitalisation is correlated with advanced age and severity of underlying illness, and increases the probability of C. difficile acquisition from the environment and exposure to antibiotics. Although almost all antibiotics have been have been associated with CDI, clindamycin, cephalosporins, carbapenems and fluoroquinolones are most frequently associated with infection. 10, 11 Antibiotic stewardship reduces unnecessary antibiotic use in hospitals 12 and is crucial to controlling CDI in HCFs alongside surveillance, isolation precautions, hand hygiene and environmental cleaning. 8, 13 Limiting antibiotic use effectively reduces the incidence of CDI in HCFs, 14 however, CDI remains a significant problem and has been named by the US Centers for Disease Control as an urgent threat to public health. 15 It is therefore important to monitor changes in risk for HCFA-CDI associated with changes in antibiotic usage and changing C.difficile epidemiology. The objective of this systematic review is to update the evidence for epidemiological associations between specific antibiotic classes and HCFA-CDI. This review updates earlier reviews that covered studies conducted up to 2012, 10, 11 to include studies undertaken between 2013 and 2020.

The study has been conducted in accordance with the PRISMA statement. 16 The objectives, inclusion criteria and methods for analysis were specified in advance and registered with PROSPERO (CRD42020181817).

Studies were eligible for inclusion in the review if they were conducted among hospital inpatients, measured any exposure to individual antibiotics or antibiotic classes prior to development of the outcome, included a comparison group, and measured the occurrence of HA-CDI as an outcome. Study designs eligible for inclusion consisted of case-control studies, cohort studies, analytical crosssectional studies and randomised controlled trials (if they reported the risk associated with the exposure).

Studies were excluded if they investigated risk factors for severe disease, relapse or recurrence, asymptomatic colonisation, or were specific studies of paediatric populations. Studies that did not 4 report exposure to specific antibiotics or antibiotic classes were also excluded, as were studies examining community associated infection or did not adequately exclude CA. Case reports, case series, and descriptive cross-sectional studies (i.e. those without comparison groups) were excluded. The review was limited to English-language publications, however, non-English articles were included in searches and their abstracts and full texts were assessed for eligibility.

PubMed, Scopus and Web of Science Core Collection were searched on 21 st April 2020 for studies published since 1 st January 2013. WorldCat (www.worldcat.org) and Proquest Dissertations and Theses (PQDT www.proquest.com) were used to search for dissertations and theses. Final follow up searches to 31 st December 2020 were conducted on 11 th February 2021.

The search strategy used was consistent with the previous review. 10 The full search strategy for each database presented in the Supplementary file. Search results were exported to Endnote X9.1, which was used to identify and remove duplicates prior to importing to Covidence (www.covidence.org) for title and abstract screening.

Titles and abstracts were screened to eliminate irrelevant studies. Full text articles were then inspected for eligibility. Studies were classified as confirmed HCFA-CDI if they included a clear definition of HCFA-acquisition of CDI, or probable HCFA-CDI on the basis of information provided in the report, e.g. evidence that the minimum length of stay until onset of symptoms was >48 hours. Studies that had been excluded from the previous review because they did not use an explicit definition of HA were re-evaluated and subsequently included in this review if there was sufficient evidence that HA-CDI was probable.

Data were extracted from each study using a pro forma template that included the study characteristics (citation, country, setting, study period based on earliest time point, study population, study design, HCFA-CDI case and non-case definitions, antibiotic name, exposure period and timing, comparison group), number of subjects in exposure categories for cases and non-cases, effect estimates (odds ratio; relative risk) and 95% confidence intervals.

Antibiotic exposures were categorised into their main classes with additional sub-group categorisation for cephalosporins (1 st , 2 nd , 3 rd , 4 th generation), penicillins (ampicillin-like drugs [aminopenicillins]; beta-lactamase inhibitor combinations; broad-spectrum [antipseudomonal] penicillins; penicillin G-like drugs [natural penicillins]) using the MSD Manual. 17 The unexposed comparator groups were categorised as no antibiotics; unexposed to antibiotic of interest; a reference antibiotic. The exposure period was classified in two ways. First, whether antibiotic administration before CDI diagnosis was recorded by the study and, second, the period of time over which antibiotic administration was measured and categorised as: during index admission; up to 1 month prior to CDI diagnosis; up to 1-2 months prior; up to 2-3 months prior; preoperative prophylaxis; during admission -prior to ICU; during ICU admission.

The non-CDI case groups were recorded as asymptomatic or symptomatic (patients had diarrhoea but tested negative for C. difficile). Study setting was classified according to geographic region (North America, Latin America, Europe, East Asia & Pacific) and patient population: general adult inpatients and specific clinical sub-groups (HA-pneumonia, HA-diarrhoea, antibiotic treatment, ICU 5 patients, COPD patients, C. difficile colonised, haematology-oncology patients, surgicalgastrointestinal, surgical -non-gastrointestinal, type 2 diabetes).

The Newcastle-Ottawa Scale for the Assessment of Quality (NOS) was used to assess study quality. 18 The NOS comprises nine items across the domains of: selection, comparability, and exposure (casecontrol studies) or outcome (cohort studies). Each accomplished item receives one point and studies are classified as high quality (score 7-9), moderate quality (score 4-6), or poor quality (score 0-3). Important confounding domains considered in the study for assessment of comparability were identified from previous studies and included: age, comorbidities, severity of underlying disease (1 point), and healthcare facility exposure or other treatment (1 point) 9 . Poor quality studies were not excluded from the review, instead overall study quality and level of comparability were explored as potential sources of heterogeneity.

Data were entered into Excel for coding and exported to Stata version 14 for analysis. A quantitative descriptive analysis summarising the characteristics of included studies was undertaken, presented as counts and percentages.

To assess the association between each antibiotic class and HA-CDI, a pooled random effects analysis using the DerSimonian-Laird inverse variance approach was used. 19, 20 The meta-analysis was restricted to studies that used a comparison group that was unexposed to the antibiotic of interest, as this was the comparison used in most studies. As most studies reported odds ratios (OR), the most fully adjusted odds ratio was used for synthesis. Where studies reported results for multiple antibiotics within each class, without providing the relevant overall association for that class, effect estimates were combined by taking the weighted average of the log ORs, with inverse variance weights. Heterogeneity of pooled effects was assessed using the I 2 statistic, which describes the percentage of variability in the effect estimates that is due to heterogeneity rather than chance, and its chi-squared statistic for evidence of heterogeneity (p<0.10).

A sub-group analysis was used to assess study characteristics identified a priori based on previous findings as sources of heterogeneity. Specific characteristics investigated included setting (geographic region, time period when the study was conducted, patient population), exposure measurement (time period prior to CDI diagnosis, measurement after onset), and methodology (study design, HA definition, non-case comparison group, study quality, confounder adjustment). Only antibiotic classes with data from at least 10 studies were included in the sub-group analysis. The sub-group pooled associations and their corresponding I 2 statistics and tau-squared statistics (for between study variance) were examined. The overall association between the study characteristic was investigated using random effects metaregression; variables associated with between study variation at p<=0.10 in a bivariate analysis were included in multivariable models.

Funnel plot analysis was used to assess bias due to missing results (publication bias). 21

The PRISMA diagram is presented in Figure 1 . Of 804 titles and abstracts of non-duplicate articles screened, 197 full text articles were assessed for eligibility and 23 were included in the review along with 16 studies from the previous review covering studies until the end of 2012 (total 39). Of the 23 studies identified from the latest searches, only 11 studies reported a clear definition of hospital acquisition with a further 12 deemed probable HCFA-CDI based on information available in the 6 article. Two papers previously excluded from the earlier review (consisting of 14 studies) were identified as probable HCFA-CDI and subsequently added to this update.

Four studies of patients undergoing solid organ transplants [22] [23] [24] [25] and five stem cell transplant studies [26] [27] [28] [29] [30] were excluded because of the long follow times after discharge precluding establishment of HA. For example, in the study by Cusini et al. 22 kidney transplant patients were followed for 2 years of which only 56% of CDI cases were deemed nosocomial.

The characteristics of the included studies identified are summarised in Table 1 . Full details of each study identified are provided in the supplementary file (Table S1 ). Most studies were either cohort or case-control studies, where cohort studies were the predominant design in articles published since 2013, compared to case-control studies in earlier articles. Compared to the earlier review, a more diverse range of patient groups was investigated in the recent studies and from a wider range of geographic regions. Of the 18 cohort studies, 16 were clinical cohort studies, examining specific inpatient sub-groups. Most studies at both time points used patients not diagnosed with CDI as the non-case group, with 23% using symptomatic non-cases. Most studies (87%) used non-exposure to the antibiotic of interest as the unexposed comparator.

Most studies were graded as medium or high quality (Table 1 ). Full details of the NOS quality appraisal score for each study is summarised in the supplementary file (Table S2 ). Selection and confounding were important sources of error, with only 17 (43%) studies attaining the maximum score for selection and 15 (38%) studies reaching the maximum score for comparability; 86% of casecontrol designs scored 3/3 for exposure measurement, and 50% of cohort designs scored 3/3 for outcome measurement.

Studies that used an exposure comparison group consisting of those not exposed to the antibiotic measured were included in meta-analyses (n=34).

For non-beta-lactam antibiotic classes (Figures 2 and 3 ), the strongest evidence for an association was seen for quinolones (fluoroquinolones) and lincosamides (clindamycin). Overall, quinolones were associated with a 34% increased odds of HCFA-CDI (OR=1.34, 95% CI=1.13-1.60), although individual ORs ranged from 0.15 to 15.30. Excluding the study with an extremely small outlier association (0.15) made little change to the pooled result (OR=1.37, 95%CI=1.15-1.63; I 2 =85.4%). Lincosamides were associated with a 56% increased odds of HCFA-CDI (OR=1.56, 95% CI=1.13-2.14), with individual study ORs ranging from 0.39 to 9.10. Weak positive pooled associations were observed for aminoglycosides, macrolides, and sulphonamides-trimethoprim, and a wide range in individual study effect sizes was found. There was strong heterogeneity observed for each of these classes, with ORs distributed in both positive and negative directions. Associations were found also for antibiotics used to treat CDI, particularly vancomycin (class glycopeptides) with a pooled OR of 1.91 (95%CI 1.32-2.78). Figure 4 displays the results for beta-lactam classes. The strongest association was seen for carbapenems (OR=2.55, 95%CI=1.83-3.55), with penicillins and cephalosporins associated with 33% and 79% increased odds of HA-CDI, respectively. There was substantial heterogeneity for all three main classes. For carbapenems, all ORs except one were in the positive direction ranging from 0.79 to 14.13. For penicillins and cephalosporins there were a number of ORs in opposite directions.

7 Beta-lactamase inhibitor combination penicillin antibiotics were the most frequently reported penicillin sub-class ( Figure 5 ). ORs ranged from 0.47 to 17.40 (three studies had OR<1) with a pooled OR of 1.43 (95%CI 1.16-1.77). There was little evidence of an association for aminopenicillins, and few studies reported data for broad-spectrum or penicillinase-resistant penicillins.

For cephalosporins, 3 rd and 4 th generation classes were associated with a doubling of the odds of HA-CDI, 2 nd generation cephalosporins with a 58% increased odds of HA-CDI, and no evidence for an association with 1 st generation cephalosporins ( Figure 6 ). The individual study findings for 4 th generation cephalosporins were the most homogenous, with all effect sizes in a positive direction and ranging from 1.1 to 3.24.

Ten antibiotic classes with a minimum of 10 studies and where more than 50% of the variation was due to heterogeneity were included in the sub-group analysis and metaregression. The results of subgroup analyses are presented as supplementary figures (Figures S1-S3). Although several sources of heterogeneity were identified for eight antibiotic classes, there were no sources common to all classes ( Table 2 ). The most common sources were geographic region, exposure measurement period, and measurement of exposure after onset of symptoms.

Studies conducted in Latin America, East Asia and Pacific regions reported stronger associations for combination penicillins, aminoglycosides and trimethoprim-sulfonamides, approximately 3-4 times higher than those reported by North American studies. Measurement of the antibiotic exposure after onset of symptoms was also a source of heterogeneity for aminoglycosides, with associations twice that of studies that collected exposure information preceding onset of symptoms. A longer window of antibiotic exposure measurement was associated with all three cephalosporin sub-classes in unadjusted analyses, and associations were attenuated in multivariable models. Other sources of heterogeneity for cephalosporins included definition of HCF acquisition (2 nd and 3 rd generation), study population (3 rd generation) and study design (3 rd generation). Studies using patient sub-groups tended to have weaker associations for a number of antibiotic classes, and this was a strong source of heterogeneity for associations with macrolides and 3rd generation cephalosporins, with effect sizes half of that seen in studies of general inpatients.

Five studies were not included in the meta-analysis due to differences in antibiotic exposure measurement; two Canadian studies used no antibiotic exposure as the reference category, 31, 32 one study examined duration and dosage of antibiotic exposure 33 and two UK studies used historical controls to examine the impact of changes to antibiotic formulary changes. 34, 35 The main results are summarised below.

A case-cohort study of adult inpatients of a large tertiary hospital in Canada measured the risk of HA-CDI associated with exposure to various antibiotic classes compared to patients with no antibiotic exposure in the five days prior to developing symptoms. 31 After adjusting for age, gender, hospital exposure, and infection pressure, the incidence of CDI was 2-3 times higher for penicillins, cephalosporins, fluoroquinolones, and carbapenems. The second Canadian study compared the risk of CDI for various antibiotics according to whether CDI developed during or following cessation of exposure compared to no exposure, taking into account competing events of death or discharge. 32 They found the risk of CDI was greatest in the period following exposure to penicillins, quinolones, macrolides, aminoglycosides or clindamycin. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ;

8 The cohort study of ICU patients with hospital-acquired pneumonia by Li et al. 33 reported the mean duration of treatment and total dose per patient to be higher in patients who developed CDI for broad-spectrum cephalosporins, carbapenem, and oxacephems, although not all of the differences were statistically significant.

Two UK clinical cohort studies used historical controls to examine the impact of changes to antibiotic formulary changes. In patients with severe hospital-acquired pneumonia, none of the patients treated with amoxicillin plus temocillin (n=98) developed CDI compared to 7.4% (7/94) of patients who had previously been treated with piperacillin-tazobactam (both beta-lactamase inhibitor combinations). 34 In a study comparing gentamicin (aminoglycoside) with cefuroxime (2 nd generation cephalosporin) for total hip and knee replacement surgery prophylaxis, there were no CDI cases in the gentamicin group (n=2101) compared to 11 cases (0.2%) in the cefuroxime group (n=6094). 35 

Thirteen non-English language articles were identified in the current review of which only one study was eligible for inclusion in the review. 36 The case-control study of immunosuppressed patients reported exposure to fluoroquinolones was higher in CDI cases (36%) than controls (28%) and exposures to 2 nd or 3 rd generation cephalosporins was lower in cases (6%) than controls (14%). Details of the non-English language studies are summarised in Table S3 .

Supplementary Figure S4 displays the funnel plots for the studies included in the meta-analyses of each main antibiotic class. Although there was not strong evidence for bias due to non-reporting of small studies, several of the plots reflect asymmetry associated with the heterogeneity previously addressed.

This systematic review updates the findings from two previous reviews through to 2020. Twenty-one studies published since 2013 were included in this review, in addition to 16 studies identified in earlier reviews. 10, 11 The main findings indicate that carbapenems and 3 rd and 4 th generation cephalosporin antibiotics remain most strongly associated with HCFA-CDI, with cases more than twice as likely to have recent exposure to these antibiotics prior to developing CDI. Modest associations (OR>1.5) were observed for quinolones (predominantly fluoroquinolones), lincosamides (namely clindamycin), 2 nd generation cephalosporins, and beta-lactamase inhibitor combination penicillin antibiotics. Individual study effect sizes were variable and heterogeneity was a common problem observed for most antibiotic classes. However, the risk of CDI for a given antibiotic will depend on the local prevalence of strains that are resistant to the particular antibiotic and a certain degree of heterogeneity is therefore to be expected. 8 Since 2013, there have been more studies conducted in a wider range of countries, including three from Latin America (covering Argentina, Mexico, Brazil) 37, 38 and four from East Asia and Pacific countries (China, Korea, Malaysia, Taiwan). 33, [39] [40] [41] The studies from Latin America and East Asia-Pacific regions reported stronger associations for a number of antibiotic classes with HCFA-CDI. With only a small number of studies from these regions conclusions regarding such differences are limited and further studies are needed.

In addition, a more diverse range of patient populations have been studied since 2013, with an increase in focused studies on clinical patient groups, such as surgical 35, 42, 43 and ICU patients, 44 or patients with particular conditions such as HA-pneumonia, 33, 34, 45 compared to earlier studies that is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; 9 predominantly studied general inpatients. Studies using patient sub-groups tended to have weaker associations. A potential explanation is that studies of patient sub-groups had shorter periods of antibiotic exposure measurement. For example, in studies assessing 3 rd generation cephalosporins, three out of seven studies of general inpatients measured exposure up to three months prior to CDI, whereas no study that was restricted to patient sub-groups used a three-month exposure window. Studies that used longer windows of exposure measurement had stronger effect sizes which could reflect a protracted time at risk for CDI following antibiotic treatment. Previous studies have shown that the risk of CDI declines between 1-2 months following cessation of antibiotic treatment. 31, 46 Alternatively, it could mean that these studies simply picked up more exposed individuals, resulting in differential misclassification if this was not consistent for cases and non-cases.

Another exposure measurement source of heterogeneity was the inadequate description or failure to limit recording of antibiotic exposure to a period preceding onset or diagnosis of CDI, producing biased effect estimates. This could explain the associations found for antibiotics used to treat CDI such as vancomycin and metronidazole (glycopeptide and nitromidazole classes, respectively), although this could not be established in this review, and both are able to incite CDI. 47 Future studies should clearly report the parameters of exposure measurement, including all sources of information on exposure, as it was often unclear particularly in studies with a longer exposure window whether in-hospital prescription only was recorded, or whether prescription in the community setting was included. Information on dose-response relationships is generally lacking and studies investigating the risk of HCF-CDI associated with the timing and duration of antibiotic exposure are needed.

Other methodological differences in studies, such as the use of a clear definition of hospitalacquisition, the choice of non-case comparison group, and group comparability on confounding factors, were not consistent sources of heterogeneity, but had varying influences on study results. A variety of diagnostic laboratory testing methods that have varying sensitivity and specificity were used by studies included in the review. With increasing computing power, cohort studies utilising routinely collected patient data have increased in recent years -investigators should clearly report surveillance definitions, criteria and laboratory methods for diagnosis of CDI in their institutions, and how these align with relevant current guidelines. 8, 48 Studies are subject to diagnostic suspicion bias if patients exposed to antibiotics are more likely to be tested for C. difficile.

This review provides the most up to date synthesis of evidence in relation to the risk of HA-CDI associated with exposure to specific antibiotic classes. However, the review is limited by the availability of a single reviewer to select, extract and critically appraise the studies. Since the previous review that covered studies published up to the end of 2012, there has been a marked increase in the overall number of studies eligible for inclusion. As found previously, studies were variable in methodological quality and quality of reporting results. Studies from the Latin America and East Asia-Pacific regions have increased, although studies were predominantly conducted in North America or Europe, and more studies outside of these settings are needed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Note: "Other" sub-group refers to a circumstance where data on general beta-lactam exposure were reported. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.21.21252172 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.21.21252172 doi: medRxiv preprint Scopus (TITLE-ABS-KEY("clostridium difficile" OR "clostridioides difficile") AND TITLE-ABS-KEY(diarrhe?a OR colitis) AND TITLE-ABS-KEY(anti-infective OR antimicrobial OR antibiotic) AND TITLE-ABS-KEY("case?control" OR cohort OR epidemiology)) AND PUBDATETXT("April 2020" or "May 2020" or "June 2020" or "July 2020" or "August 2020" or "September 2020" or "October 2020" or "November 2020" or "December 2020") 9 3

Web of Science Core Collection TS=((((("clostridium difficile" OR "clostridioides difficile") AND ( "diarrhe?a" OR colitis) AND ("anti-infective" OR antibiotic OR antimicrobial) AND ( "case?control" OR cohort OR retrospective OR prospective) )))) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2020 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 23, 2021. ; 

The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study

Risk of Clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile

Clostridium difficile infection: the role of antibiotics in outbreak control, epidemiology and treatment

Influence of antibiotics and case exposure on hospital-acquired Clostridium difficile infection independent of illness severity

Postoperative diarrhea and high ostomy output impact postoperative outcomes after elective colon and rectal operations regardless of Clostridium difficile infection

Epidemiology and risk factors for Clostridium difficile infection in critically ill patients in Spain: The PROCRID study

Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit

Hospital-acquired Clostridium difficile infection among patients with type 2 diabetes mellitus in acute medical wards

A multi-institutional cohort study confirming the risks of Clostridium difficile infection associated with prolonged antibiotic prophylaxis

Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China

Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization

Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico

Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil

Characteristics, risk factors and outcomes of Clostridium difficile infections in Greek Intensive Care Units

Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres

Analysis of risk factors and clinical manifestations associated with Clostridium difficile disease in Serbian hospitalized patients

Identification of Clostridium difficile asymptomatic carriers in a tertiary care hospital

Analyzing Risk Factors for Healthcare-Associated Infections Using Multiple Methodological Approaches

Changing antibiotic prophylaxis for primary joint arthroplasty affects postoperative complication rates and bacterial spectrum

Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids

Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics

Evaluating the Risk Factors for Hospital-Onset Clostridium difficile Infections in a Large Healthcare System

The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study

Clinical and demographic profile and risk factors for Clostridium difficile infection

Clostridium difficile in visceral surgery

Clostridium difficile in inflammatory bowel disease

The effect of Clostridium difficile infection on length of hospital stay. A cohort study

Campylobacteriosis at the Department of Infectious Diseases of the University Hospital Brno in 2011-2013: a retrospective study

Clostridium difficile ": Incidencia, epidemiología, características clínicas, factores de riesgo de gravedad y recurrencia

Impact des caractéristiques des hôpitaux québécois sur le taux d'incidence d'infection à Clostridium difficile

La réévaluation des traitements par inhibiteur de la pompe à proton chez les patients traités au long cours en médecine générale dans l

Clostridium difficile ribotype 027 is a challenge

Epidemiology of infection caused by Clostridium difficile

Epidemiological characteristics of nosocomial diarrhea caused by Clostridium difficile in a tertiary level hospital in Serbia

Note: Effect estimates (x-axis) are plotted against study size (y-axis) as measured by the standard errors of the exposure effect. The Y-axis is plotted on a reverse scale so that the larger studies are at the top (i.e. have smaller standard errors). The effect estimates from smaller studies should scatter more widely at the bottom, with the spread narrowing among larger studies. In the absence of bias and between study heterogeneity, the scatter will be due to sampling variation alone and the plot will resemble a symmetrical inverted funnel.